Loading please wait...
Loading please wait...
An Integrated Biomarker and MRI Risk Assessment Approach to Prostate Cancer Diagnosis
Prostate cancer diagnostic guidelines aim to minimize over diagnosis of clinically insignificant prostate cancer (Gleason6/GG1). The clinical question before us is how do we enable the best balance, helping to increase compliance with the biopsy recommendation for patients at higher-risk while providing greater assurance for low-risk patients in an informed shared decision to defer biopsy? There is a vital need to understand better how mpMRI and the various biomarkers can be integrated into the prostate cancer diagnostic algorithm. All risk stratification tools, including mpMRI or biomarkers, have individual strengths and limitations. Complementary risk assessment methods can balance out limitations, and leverage the respective strengths, for stronger clinical assessment. This webinar discusses how biomarkers, specifically the ExoDx Prostate Test, might be considered, in combination with MRI imaging in men considering diagnostic prostate biopsy.
The ExoDx™ Prostate Test & mpMRI - A Complementary Approach
Dr. David M. Albala
Dr. David M. Albala completed his medical school training at Michigan State University and went on to complete his surgical residency at the Dartmouth-Hitchcock Medical Center. He practiced at Loyola University Medical Center in Chicago and became a Professor in Urology and Radiology in eight years. After 10 years, he became a tenured Professor at Duke University Medical Center in North Carolina. At Duke, he was Co-Director of the Endourology fellowship and Director for the Center of Minimally Invasive and Robotic Urological Surgery. He has served on the LUGPA Board of Directors since 2016 and was listed by Stanford University in a 2021 study as one of the top 2% of Urologists/Nephrologists in the world. He is considered a national and international authority in laparoscopic and robotic urological surgery and has been an active teacher in this area for over 20 years. In addition, other clinical interests of his include minimally invasive treatment of benign prostatic hypertrophy (BPH) and the use of fibrin sealants in surgery.
... Show MoreQ&A Session Recording
00:22:51
mpMRI and Biomarkers Webinar
mpMRI and Biomarkers Complementary as Risk Assessment Methods in the Early Detection
00:28:37